Note 15 - Segments - Operations by Segment (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenue from Contract with Customer, Excluding Assessed Tax	$ 173,632	$ 178,595	$ 529,504	$ 681,591
Operating income (loss)	14,216	(64,407)	(118,926)	(87,975)
Depreciation and amortization	24,163	26,183	74,137	79,315
Loss from investment in investees	(3)	(20)	(7)	(99)
UNITED STATES
Revenue from Contract with Customer, Excluding Assessed Tax	132,663	139,043	410,422	462,987
IRELAND
Revenue from Contract with Customer, Excluding Assessed Tax	11,514	8,654	30,579	121,249
CHILE
Revenue from Contract with Customer, Excluding Assessed Tax	16,576	16,932	49,067	52,427
SPAIN
Revenue from Contract with Customer, Excluding Assessed Tax	6,297	4,349	17,828	16,427
ISRAEL
Revenue from Contract with Customer, Excluding Assessed Tax	196	3,155	797	9,388
MEXICO
Revenue from Contract with Customer, Excluding Assessed Tax	5,630	5,897	18,621	17,447
Other Countries [Member]
Revenue from Contract with Customer, Excluding Assessed Tax	756	565	2,190	1,666
Service [Member]
Revenue from Contract with Customer, Excluding Assessed Tax	121,271	131,679	377,557	391,100
Product [Member]
Revenue from Contract with Customer, Excluding Assessed Tax	39,143	40,670	117,675	124,553
Transfer of Intellectual Property and Other [Member]
Revenue from Contract with Customer, Excluding Assessed Tax	13,218	6,246	34,272	165,938
Operating Segments [Member] | Pharmaceutical [Member]
Operating income (loss)	(32,196)	(25,375)	(84,697)	57,210
Depreciation and amortization	18,043	17,807	53,899	53,649
Loss from investment in investees	(3)	(20)	(7)	(99)
Operating Segments [Member] | Pharmaceutical [Member] | Service [Member]
Revenue from Contract with Customer, Excluding Assessed Tax	0	0	0	0
Operating Segments [Member] | Pharmaceutical [Member] | Product [Member]
Revenue from Contract with Customer, Excluding Assessed Tax	39,143	40,670	117,675	124,553
Operating Segments [Member] | Pharmaceutical [Member] | Transfer of Intellectual Property and Other [Member]
Revenue from Contract with Customer, Excluding Assessed Tax	13,218	6,246	34,272	165,938
Operating Segments [Member] | Diagnostics [Member]
Operating income (loss)	58,541	(29,081)	(2,443)	(113,344)
Depreciation and amortization	6,120	8,376	20,238	25,666
Loss from investment in investees	0	0	0	0
Operating Segments [Member] | Diagnostics [Member] | Service [Member]
Revenue from Contract with Customer, Excluding Assessed Tax	121,271	131,679	377,557	391,100
Operating Segments [Member] | Diagnostics [Member] | Product [Member]
Revenue from Contract with Customer, Excluding Assessed Tax	0	0	0	0
Operating Segments [Member] | Diagnostics [Member] | Transfer of Intellectual Property and Other [Member]
Revenue from Contract with Customer, Excluding Assessed Tax	0	0	0	0
Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]
Operating income (loss)	(12,129)	(9,951)	(31,786)	(31,841)
Depreciation and amortization	0	0	0	0
Loss from investment in investees	0	0	0	0
Segment Reporting, Reconciling Item, Corporate Nonsegment [Member] | Service [Member]
Revenue from Contract with Customer, Excluding Assessed Tax	0	0	0	0
Segment Reporting, Reconciling Item, Corporate Nonsegment [Member] | Product [Member]
Revenue from Contract with Customer, Excluding Assessed Tax	0	0	0	0
Segment Reporting, Reconciling Item, Corporate Nonsegment [Member] | Transfer of Intellectual Property and Other [Member]
Revenue from Contract with Customer, Excluding Assessed Tax	$ 0	$ 0	$ 0	$ 0